SCHEMBL222933

SCHEMBL222933

[CH]1NCCc2cc3ccccc3cc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 1/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
GAA P10253 2/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33
POLB P06746 1/20 0.33
HPGD P15428 1/20 0.33
ALOX15 P16050 1/20 0.33
ALOX12 P18054 1/20 0.33
CASP1 P29466 1/20 0.33
MPI P34949 1/20 0.33
HTT P42858 1/20 0.33
CASP7 P55210 1/20 0.33
HSD17B10 Q99714 1/20 0.33
KDM1A O60341 1/20 0.33
PNMT P11086 1/20 0.33
CD44 P16070 1/20 0.33
MAOB P27338 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL222891 0.83 MEN1 (0.39) MEN1KMT2A
SCHEMBL19579719 0.74 HTR2C (0.48) HTR2CGAAPNMTCD44MAOB
SCHEMBL5254986 0.72 PARP10 (0.49) HTR2CMEN1KMT2AGAAALDH1A1
SCHEMBL6307312 0.72 HTR2C (0.64) HTR2CMEN1KMT2APNMTCD44
SCHEMBL222038 0.71 ALDH1A1 (0.42) HTR2CMEN1KMT2AGAAALDH1A1
SCHEMBL4455694 0.71 ALDH1A1 (0.42) HTR2CMEN1KMT2AGAAALDH1A1
SCHEMBL9819791 0.68 MEN1 (0.40) MEN1KMT2AALDH1A1ALOX12HSD17B10
SCHEMBL20520367 0.68 PARP10 (0.44) HTR2CALDH1A1KDM1APRCPHTR5A
SCHEMBL9756716 0.68 DRD2 (0.46) KDM1A
SCHEMBL14482014 0.67 MEN1 (0.52) MEN1KMT2AALDH1A1TP53HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024150222-A1 IONIZABLE LIPIDS AND NANOPARTICLES COMPRISING SAME MANA BIO LTD. (IL) 2024-07-18 WO disclosed
CN-118284426-A Ophthalmic compositions and methods of use thereof 塔西亚制药公司 2024-07-02 CN disclosed
CN-118146635-A Coating composition with polysiloxane modified carbon nanoparticles NGNT材料科学公司 2024-06-07 CN disclosed
EP-4376837-A1 COMPOUNDS FOR NEUTROPHIL ROS INHIBITION Immunyx Pharma Ltd. (IL) 2024-06-05 EP disclosed
US-20240156742-A1 TARGETED MULTIFUNCTIONAL NANOSTRUCTURED LIPID CARRIERS TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2024-05-16 US disclosed
US-20240148886-A1 INTRACELLULAR DELIVERY COMPOSITIONS BIOND BIOLOGICS LTD. (IL) 2024-05-09 US disclosed
WO-2024069634-A1 MICROTUBULE TARGETING AGENTS Ariel Scientific Innovations Ltd. (IL) 2024-04-04 WO disclosed
WO-2024052923-A1 IONIZABLE LIPIDS AND COMPOSITIONS COMPRISING SAME BARCODE NANOTECH LTD. (IL) 2024-03-14 WO disclosed
CN-117651568-A Intracellular delivery compositions 比昂生物制剂公司 2024-03-05 CN disclosed
EP-4326332-A1 INTRACELLULAR DELIVERY COMPOSITIONS Biond Biologics Ltd. (IL) 2024-02-28 EP disclosed
US-6133409-A REACTING A SOLID SUPPORT-BOUND N-ALKYLATED HYDROXAMIC ACID WITH A CARBON-NITROGEN CLEAVING ORGANOMETALLIC COMPUND TO LIBERATE THE PRODUCT KETONE AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 2000-10-17 US disclosed
US-6127515-A Functionalized resin for the synthesis of amides and peptides AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 2000-10-03 US disclosed
WO-2000040547-A1 α-SUBSTITUTION OF UNPROTECTED β-AMINO ESTER COMPOUNDS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 2000-07-13 WO disclosed
WO-2000039087-A2 SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 2000-07-06 WO disclosed
WO-1999067192-A2 PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDE, KETONE, OXIME, AMINE, HYDROXAMIC ACID AND α,β-UNSATURATED CARBOXYLIC ACID AND ALDEHYDE COMPOUNDS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 1999-12-29 WO disclosed
WO-1999037304-A1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 1999-07-29 WO disclosed
EP-0931060-A1 SUBSTITUTED N- (AMINOIMINOMETHYL OR AMINOMETHYL)PHENYL]PROPYL AMIDES RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) 1999-07-28 EP disclosed
WO-1999031491-A1 METHOD AND REAGENTS FOR THE QUANTIFICATION OF SOLID-PHASE REACTIONS USING FLUORINE NMR AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 1999-06-24 WO disclosed
WO-1999025752-A1 FUNCTIONALIZED RESIN FOR THE SYNTHESIS OF AMIDES AND PEPTIDES AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 1999-05-27 WO disclosed
WO-1999000356-A1 SUBSTITUTED N-[(AMINOIMINOMETHYL OR AMINOMETHYL)PHENYL]PROPYL AMIDES RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) 1999-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240156742-A1 TARGETED MULTIFUNCTIONAL NANOSTRUCTURED LIPID CARRIERS LCAT, CD47, PHOSPHO1 HTR2C 4752/4885MEN1 762/4885KMT2A 419/4885
US-20240148886-A1 INTRACELLULAR DELIVERY COMPOSITIONS ACTB, CHERP, EEA1 HTR2C 4528/4885MEN1 2434/4885KMT2A 4267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.